Shares of Pacira Pharmaceuticals (NASDAQ: PCRX) are up 12% following positive Phase IV data from the TKA study. The study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE